Release Details
Voyager Therapeutics to Host R&D Day and Webcast on April 29, 2016
During the R&D day, presentations by members of Voyager’s management team and guest speakers will include:
- Unmet Medical Needs in Parkinson’s Disease and Potential Treatment Using Gene Therapy
Andrew S. Feigin , M.D.
Director, Experimental Therapeutics for Movement Disorders,Feinstein Institute
Director, Huntington’sDisease Society of America Center of Excellence ,North Shore University Hospital
- Overview of VY-AADC01 for Parkinson’s Disease
Bernard Ravina , M.D.
Vice President, Clinical Development,Voyager Therapeutics
- Role of Superoxide Dismutase 1 in ALS and the Potential for Targeted Treatment Using Gene Therapy
Robert H. Brown , D.Phil., M.D.
Professor and Chair of Neurology,University of Massachusetts Medical School
Director,Day Neuromuscular Research Laboratory ,University of Massachusetts Medical School
- Overview of VY-SOD101 for a Monogenic Form of ALS
Dinah Sah , Ph.D.
Senior Vice President, Neuroscience,Voyager Therapeutics
- New Opportunities in CNS Gene Therapy
Steve Paul , M.D.
President and CEO,Voyager Therapeutics
Webcast Information
A live audio webcast of the R&D Day and replay will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. A replay of the presentation will be posted on the Voyager website approximately one hour after the live event and will be available for 30 days following the presentation.
About
Investor Contact:Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 sarah@sternir.com Media:Katie Engleman Pure Communications, Inc. 910-509-3977 Katie@purecommunicationsinc.com